Related Experiment Video
Updated: Feb 15, 2026

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM
Xiang Zhang1, Zhen Zhang2, Qing Zhang2
1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Abstract:
Although zinc finger E-box binding homeobox 1 (ZEB1) has been identified as a key factor in the regulation of breast cancer differentiation and metastasis, its potential role in modulating tumor chemoresistance has not been fully understood. Here, through the study of specimens from a large cohort of human breast cancer subjects, we showed that patients with tumors that expressed high levels of ZEB1 responded poorly to chemotherapy. Moreover, ZEB1 expression was positively correlated with expression of B-cell lymphoma-extra large (Bcl-xL) and cyclin D1, which are key components of tumor chemoresistant mechanisms. At the molecular level, ectopic expression of ZEB1 impaired the responsiveness of breast cancer cells to genotoxic drug treatment, such as epirubicin (EPI). During this process, ZEB1 transcriptionally activated the expression of ataxia-telangiectasia mutated (ATM) kinase by forming a ZEB1/p300/PCAF complex on its promoter, leading to increased homologous recombination (HR)-mediated DNA damage repair and the clearance of DNA breaks. Using a nude mouse xenograft model, we further confirmed that ectopic expression of ZEB1 decreased breast cancer responsiveness to EPI treatment in vivo. Collectively, our findings suggest that ZEB1 is a crucial determinant of chemotherapeutic resistance in breast cancer.
Insights
High ZEB1 expression in breast cancer predicts poor response to chemotherapy by promoting DNA repair. This suggests ZEB1 is a key factor in developing chemoresistance in breast cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Zinc finger E-box binding homeobox 1 (ZEB1) is implicated in breast cancer progression.
- The role of ZEB1 in chemoresistance remains unclear.
Purpose of the Study:
- To investigate the role of ZEB1 in breast cancer chemoresistance.
- To elucidate the molecular mechanisms underlying ZEB1-mediated chemoresistance.
Main Methods:
- Analysis of ZEB1 expression in human breast cancer specimens.
- In vitro studies using breast cancer cell lines with ectopic ZEB1 expression.
- In vivo studies using a nude mouse xenograft model.
- Investigation of molecular interactions involving ZEB1, Bcl-xL, cyclin D1, ATM, and DNA repair pathways.
Main Results:
- High ZEB1 expression correlates with poor response to chemotherapy in breast cancer patients.
- ZEB1 expression is positively associated with Bcl-xL and cyclin D1.
- Ectopic ZEB1 expression reduces sensitivity to epirubicin (EPI) in vitro and in vivo.
- ZEB1 activates ATM kinase expression via a ZEB1/p300/PCAF complex, enhancing DNA repair.
Conclusions:
- ZEB1 is a critical determinant of chemoresistance in breast cancer.
- ZEB1 promotes chemoresistance by enhancing DNA damage repair through ATM activation.
- Targeting ZEB1 may represent a therapeutic strategy to overcome chemotherapy resistance.
Related Concept Videos
Treatment Resistant Cancers
Resistivity
Resistance
Equivalent Resistance
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their...
Rolling Resistance
For instance, imagine a hard cylinder rolling on a comparatively soft surface. The cylinder's weight compresses the surface beneath it. As the cylinder moves, the material in front of it slows down due to...

